XORTX Therapeutics Raises USD $114,500 Through Private Placement

Author: Dylan Bailey Updated: 08-08-2025 08:00 PM

XORTX Therapeutics Completes Successful Private Placement

XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has achieved a significant milestone by successfully completing a non-brokered private placement. The company raised a total of USD $114,500 through the issuance of 156,849 units, priced at USD $0.73 per unit. This funding is crucial for advancing the company’s innovative therapies aimed at treating gout and progressive kidney disease.

Details of the Private Placement Offering

Each unit in this placement consists of one common share and one common share purchase warrant. Notably, each warrant allows the holder to purchase an additional common share at USD $1.20 for a period of 60 months following issuance. However, if the closing price of the common shares exceeds USD $2.00 for ten consecutive trading days, the warrants will be accelerated and will expire 30 business days thereafter, a strategic move that provides flexibility and leeway for investors.

Utilization of Proceeds

The funds raised through this offering will support XORTX’s gout programs and provide general corporate and working capital. This financial boost will aid in the ongoing development of the company's leading drug candidates, which aim to improve the quality of life for those suffering from gout and other related kidney diseases.

Compliance and Regulatory Details

The completion of this offering was conditionally approved by the TSX Venture Exchange (TSXV). The securities issued as part of this offering will be subject to a four-month and one-day statutory hold period, ensuring compliance with regulatory requirements and facilitating market stability.

About XORTX Therapeutics Inc.

XORTX Therapeutics is a growing pharmaceutical company recognized for its innovative approaches to treating various kidney-related conditions. The company is advancing several clinically advanced therapies, including XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injuries related to respiratory virus infections. Additionally, the company is in the pre-clinical stage of development for XRx-225, targeting Type 2 diabetic nephropathy. XORTX's mission is to mitigate the effects of aberrant purine metabolism and high uric acid levels, developing medications that improve patients' health.

Connecting with XORTX

For further inquiries or more information about XORTX’s innovative drug development, interested parties can contact:

Allen Davidoff, CEO
+1 403 455 7727
adavidoff@xortx.com

Nick Rigopulos, Director of Communications
+1 617 901 0785
nick@alpineequityadv.com

Frequently Asked Questions

What is the primary purpose of the funds raised by XORTX?

The funds are primarily intended to support the company's gout programs and general corporate needs.

How many units were issued in the private placement?

A total of 156,849 units were issued at a price of USD $0.73 per unit.

What can warrant holders do with their warrants?

Holders can purchase additional common shares at USD $1.20 per share for a period of 60 months following issuance.

Is the offering subject to any restrictions?

Yes, the securities are subject to a statutory hold period of four months and one day, as per regulatory compliance.

What innovative therapies does XORTX Therapeutics offer?

XORTX is developing therapies for gout, ADPKD, acute kidney injuries, and Type 2 diabetic nephropathy.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.